Extensive clinical study has shown the value of roflumilast and several other PDE4-selective inhibitors, such as cilomilast, in COPD, even though they do not have significant acute bronchodilator activity (reviewed in Refs. The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.